Vidaza
Drug
Celgene Corporation
Total Payments
$3.4M
Transactions
291
Doctors
57
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $984,792 | 12 | 0 |
| 2023 | $455,118 | 55 | 0 |
| 2022 | $477,235 | 31 | 5 |
| 2021 | $104,208 | 18 | 4 |
| 2020 | $277,185 | 20 | 11 |
| 2019 | $272,032 | 14 | 1 |
| 2018 | $407,722 | 31 | 17 |
| 2017 | $464,244 | 110 | 30 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.2M | 179 | 92.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $130,265 | 3 | 3.8% |
| Consulting Fee | $106,890 | 29 | 3.1% |
| Travel and Lodging | $29,189 | 47 | 0.8% |
| Food and Beverage | $3,723 | 31 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,460 | 2 | 0.1% |
Payments by Type
Research
$3.2M
179 transactions
General
$273,527
112 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CC-486 and Venetoclax for Acute Myeloid Leukemia | Celgene Corporation | $425,090 | 0 |
| Pilot Trial Evaluating CC-486 and lenalidomide in Combination with Radiotherapy For Patients with Plasmacytoma | Celgene Corporation | $243,109 | 0 |
| A Randomized Phase II Clinical Trial of Dendritic Cell/AML Fusion cell vaccine versus DC/AML fusion cell vaccine versus observation in patients who achieve a chemotherapy-induced remission | Celgene Corporation | $223,414 | 0 |
| Ph II/III RR LR MDS mono vs Placebo - A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG ) plus Best Supportive Care (BSC) versus Placebo | E.R. Squibb & Sons, L.L.C. | $166,683 | 0 |
| Randomized controlled study of post-transplant azacitidine for prevention of acute myelogenous leukemia and myelodysplastic syndrome relapse (VZ-AML-PI-0129) 2008-0503 | Celgene Corporation | $164,136 | 0 |
| A Phase 1 Study of CC-486 plus Nivolumab in Patients with Hodgkin Lymphoma Refractory to PD-1 therapy | Celgene Corporation | $145,525 | 0 |
| Effectiveness of DNA Hypomethylating Agents and Lenalidomide in Elderly Patients with Myeloid Malignancies in the United States (VZ-NI-MYELOID-PI-006039) | Celgene Corporation | $126,530 | 0 |
| VZ-AML-PI-0157 | Celgene Corporation | $125,366 | 0 |
| A phase I/Ib pilot study of cc-486 combined with lenalidomide and obinutuzumab for relapsed/refractory indolent B-cell lymphoma (iNHL) | Celgene Corporation | $122,789 | 0 |
| A phase Ib study of venetoclax, CC-486, and obinutuzumab in early follicular lymphoma | Celgene Corporation | $116,105 | 0 |
| Vidaza Non-Specific Cost | Celgene Corporation | $112,593 | 0 |
| VZ-TR-AML-PI-007061 - A pharmacodynamic measurement of DNMT1 activity during hypomethylating agent treatment | Celgene Corporation | $81,232 | 0 |
| Comparative effectiveness | E.R. Squibb & Sons, L.L.C. | $77,560 | 0 |
| A phase 3, randomized, double-blind, placebo-contr | Celgene Corporation | $77,194 | 0 |
| (CC-486-AML-001) PhIII Azacitidine + best-supportive care vs best supportive care as maintenance therapy in Subjects with AML in complete remission - Quazar | Celgene Corporation | $63,434 | 0 |
| VZ-COLO-PI-0239 | Celgene Corporation | $52,570 | 0 |
| A randomized phase II study of CHO(E)P vs Oral Azacitidine-CHO(E)P vs duvelisib-CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas. | Celgene Corporation | $52,499 | 0 |
| A Phase-2 Study of oral azacitidine (CC486) epigenetic priming and maintenance for adult AML patients treated with Allogeneic Stem Cell Transplant | Celgene Corporation | $51,510 | 0 |
| VZ-AML-PI-0157 - A Randomized Phase II Trial to Simultaneously Evaluate Two Schedules of the Histone Deacetylase Inhibitor Entinostat in Combination with 5-Azacytidine (5AC, NSC 102816) in Elderly Patients with Acute | Celgene Corporation | $51,115 | 0 |
| A Randomized Phase II Trial to Simultaneously Evaluate Two Schedules of the Histone Deacetylase Inhibitor Entinostat in Combination with 5-Azacytidine (5AC, NSC 102816) in Elderly Patients with Acute Myeloid Leukemia (AML) | Celgene Corporation | $47,909 | 0 |
Top Doctors Receiving Payments for Vidaza — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Medical Oncology | New York, NY | $2,533 | 1 |
| , MD | Hematology | San Antonio, TX | $2,533 | 1 |
| , MD | Hematology | Evanston, IL | $2,533 | 1 |
| Elihu Estey | — | Seattle, WA | $2,450 | 1 |
| Bart Scott | Medical Oncology | Seattle, WA | $2,450 | 1 |
| , M.D | Internal Medicine | Baltimore, MD | $2,450 | 1 |
| , M.D | Hematology | Albuquerque, NM | $2,142 | 1 |
| , MD PHD | Hematology & Oncology | Seattle, WA | $2,142 | 1 |
| , MD | Clinical Pathology/Laboratory Medicine | Albuquerque, NM | $2,142 | 1 |
| , MD | Medical Oncology | Gainesville, FL | $2,142 | 1 |
| , MD | Hematology | Cleveland, OH | $1,905 | 2 |
| , MD | Hematology & Oncology | Miami, FL | $1,800 | 1 |
| , M.D | Anatomic Pathology & Clinical Pathology | Salt Lake City, UT | $1,800 | 1 |
| , M.D | Hematology | Chicago, IL | $1,750 | 1 |
| , MD | Hematology | Miami, FL | $1,730 | 1 |
| , M.D | Pediatrics | New York, NY | $1,071 | 1 |
| , MD, PHD | Hematology & Oncology | Racine, WI | $1,071 | 1 |
| , M.D | Hematology | Hawthorne, NY | $1,071 | 1 |
| , M.D | Specialist | Sacramento, CA | $1,071 | 1 |
| , MD | Hematology & Oncology | Orlando, FL | $1,071 | 1 |
| , M.D | Internal Medicine | Gainesville, FL | $104.96 | 1 |
| , MD | Clinical Pathology | Nashville, TN | $104.96 | 1 |
| , MD, PHD | Pediatric Hematology-Oncology | Washington, DC | $104.96 | 1 |
| , MD | Internal Medicine | Plantation, FL | $104.96 | 1 |
| , MD | Hematology | Nashville, TN | $104.96 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $3.2M
- E.R. Squibb & Sons, L.L.C. $244,875
Product Information
- Type Drug
- Total Payments $3.4M
- Total Doctors 57
- Transactions 291
About Vidaza
Vidaza is a drug associated with $3.4M in payments to 57 healthcare providers, recorded across 291 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2017 to 2024. In 2024, $984,792 was paid across 12 transactions to 0 doctors.
The most common payment nature for Vidaza is "Unspecified" ($3.2M, 92.1% of total).
Vidaza is associated with 20 research studies, including "CC-486 and Venetoclax for Acute Myeloid Leukemia" ($425,090).